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ABSTRACT
Vaccination via aerosol has been proven to be as safe, as effective, and more appropriate
for transportation when compared with vaccination via injection. These advantages make
aerosolized vaccinations a realistic alternative to traditional injection vaccines for the
developing world, where cold chain systems are impractical and the use of hypodermic
needles can be unsafe. However, more research is needed to determine optimal
parameters for vaccine aerosolization. This thesis presents an experimental setup to test
Aerovax, a device designed to deliver aerosolized vaccinations in developing regions of
the world. The experimental technique is the first effort to optimize vaccine aerosols
across multiple variables, including input pressure, nebulizer geometry, and vaccine
reconstitution. The setup provides a pressure input, sensors for ambient properties, and a
device to measure particle size distribution.
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1. Introduction
Aerosolized vaccination is seen as a viable and necessary replacement for
traditional injection vaccines in the developing world. Currently, subcutaneous injection
requires the execution of a cold chain system' and the use of sterile hypodermic needles,
both of which present a challenge to much of the world's poor.
A major barrier to vaccine delivery in developing regions lies in maintaining
designated storage temperatures. The excessive warming or cooling of a vaccine will
cause it to lose potency, rendering it useless. Transportation to rural areas presents a
logistical challenge because it is difficult to keep vaccines at their appropriate
temperatures for the entire journey. Successful delivery relies on absolute compliance
with the cold chain system, which sets standards for personnel, equipment, and
procedures to be followed'.
Reduction of injections in the developing world would greatly benefit patients
seeking immunization, as needle misuse is a common practice among healthcare workers.
An inadequate number of biohazard waste facilities hinders safe disposal of used
needles2. Consequently, used injection equipment is very often sold, reused, or recycled
because of its commercial value, instead of being disposed of properly. Since 2003, the
World Health Organization has encouraged the use of auto-disable syringes in all
countries and has stressed that standard disposable syringes no longer be used for
immunization 2. However, as long as vaccines can be administered only by subcutaneous
injection, the reuse and misuse of needles will likely continue.
The cold chain can be eliminated with the implementation of aerosolized
vaccinations, as they would be delivered in a freeze-dried, powder form with no
temperature restrictions 3. The implementation of aerosolized vaccines would remove the
need for both cold supply chains and hypodermic needles, thus serving the developing
world efficiently and safely. However, aerosolized vaccine technology is still under
development and being tested for use.
Our lab is currently developing a new strategy called Aerovax, an inexpensive
and portable device that will provide aerosolized immunizations to healthcare's last
mile4 . Once a vaccine has reached its destination, its powder form can be aerosolized for
safe delivery to the patient.
A case example of the need for aerosolized vaccines is illustrated by the measles
epidemic. An estimated 750,000 children die from measles every year, making it one of
the most fatal respiratory diseases in children. With proper immunization, measles is
entirely preventable. For this reason, measles will be the first vaccine optimized for
aerosolization by Aerovax. Vaccination via aerosol offers a tremendous opportunity for
mass measles immunization; it has been found to vaccinate as successfully as
subcutaneous injection5 and can be administered to a wider geographical range.
The current status of aerosolized vaccination technology requires the development
of vaccine powders that maintain both their potency and a particle size that is deliverable
to the lungs via a nebulizer. The target particle size ranges from 3 Rm to 5 Pm. Particle
sizes too small have the ability to penetrate the lungs, but are not large enough to carry a
significant amount of vaccine; particle sizes too large carry a potent vaccine, but cannot
gain access to the lungs to successfully vaccinate a patient. The different sizes of vaccine
particles created by nebulization are referred to as the "particle size distribution," which
is a key parameter in the measurement of an aerosol for delivery to the respiratory
system.
This thesis aims to develop a means to measure the efficacy of powder vaccines
by developing an experimental technique to evaluate how powders respond to
nebulization. With this technique, we can define an "aerosol fingerprint"6 for a given
vaccine to be aerosolized, which will classify the optimal conditions for effective vaccine
delivery based on particle size distribution. Aerosolized vaccine particle distribution is
dependent upon input nebulizer pressure, ambient temperature, relative humidity,
nebulizer geometry, and vaccine reconstitution. The experimental setup built for this
thesis to measure particle size distribution, based on the factors just listed, is described in
the following section.
2. Experimental Setup
In the experimental setup, shown schematically in Figure 1, sensors measure
ambient temperature, ambient relative humidity, and nebulizer temperature fluctuations.
A transducer allows for regulation of the input pressure to the nebulizer. There is also a
laser system that measures particle size distribution.
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Figure 1. Schematic of the Aerovax experimental setup.
While individual parameters affecting aerosolized vaccination delivery have been
studied in various experiments, this thesis is the first attempt to optimize across all
significant variables.
2.1 Pressure
The pressure provided to the nebulizer determines the output flow rate of the
aerosol and is hypothesized to have an effect on the particle size distribution of the
vaccine. A higher flow rate will ensure less particle deposition in the nebulizer. As
recommended5' 6 , pressure values ranging between 20 psi and 70 psi will be tested. As
the main input for Aerovax, pressure plays an important role in the optimization of the
other parameters.
It is important to note that while pressure can be input from a source that runs on
electricity, it can also be delivered via a battery powered source, compressed air, or a
human powered source, such as a foot pump. This feature is incredibly valuable in
settings where either unreliable or no electricity is available, which is the case for
Aerovax's target locations.
Figure 2 shows the Craftsman 12 V air compressor that supplies pressure to the
system. It outputs 250 psi, which is much greater than the 20 psi to 70 psi required for
nebulization.
Figure 2. The compressor that supplies pressure to the setup.
A transducer, shown in Figure 3, is used to regulate the pressure through an input
voltage of 0 V to 10 V. A higher voltage input to the transducer will result in a higher
pressure output, with an approximate 27 psi maximum. A low voltage input will output a
minimum pressure of 3 psi to the nebulizer.
Figure 3. The transducer regulates pressure input from the compressor and creates the
desired output to the nebulizer for vaccine aerosolization.
In the experimental setup, the transducer is located between the compressor and
the nebulizer, as shown in Figure 1, with tubing connecting it to each. It is important to
note that the transducer will only function with a pressure input and an output line that is
not exposed to atmospheric pressure.
Figure 4 shows the configuration that was determined to be the most successful
for regulating the pressure input. The power source chosen has terminals to connect
wires to from the transducer, as well as 12 V cigarette lighter receptacle. This is a
suitable match for the compressor, as it was originally intended for automobile use and
has a cigarette lighter adapter.
Figure 4. Setup of pressure input components.
2.2 Nebulizer Temperature
During aerosolization, the solution in the nebulizer cools and concentrates. Most
of the heat loss is caused by evaporation of the nebulizer solution to saturate the gas used
to generate the aerosol, while some cooling is caused by adiabatic expansion of the gas
being generated7 . Phipps, et al. found that the temperature of a solution aerosolized
through a jet nebulizer at a low flow rate can be expected to decrease 5 to 6*C below the
ambient temperature7. Nebulizers can be expected to cause a decrease of different
temperature amounts, depending on their shape. A solution aerosolized at a high flow
rate (8L/min, for example) can be expected to decrease l l*C to 15*C. The temperature
change will typically occur within the first four minutes of aerosolization. This
significant temperature decrease can lead to an overall reduction in the particle size
7distribution, making it an important parameter to monitor.
The temperature change that occurs inside the nebulizer is measured with a
Flexible Hermetic Sealed PFA RTD Sensor Probe, shown in Figure 5. The probe can be
easily inserted into the head of the nebulizer and kept there throughout the entire
experiment without disrupting the setup, allowing for real-time measurements. The four-
wire configuration of the sensor decreases resistance from the wires and allows for easy
integration with data-logging software6 .
Figure 5. The Flexible Hermetic Sealed PFA RTD Sensor Probe, used to measure
both nebulizer and ambient temperature.
2.3 Ambient Temperature and Relative Humidity
Aerovax will be expected to operate in a wide variety of climates throughout the
developing world. In the field, ambient properties will be impossible to control;
however, it is important to observe the influence they exert, if any, on other parameters in
the setup. The measurements taken will act as a gauge for how ambient properties might
possibly alter the particle size distribution.
Relative humidity, for example, has the potential to cause post-aerosolization
6
clumping . It will be important to determine at what value and temperature this occurs, if
at all, as clumping can lead to a larger particle size measurement.
The ambient temperature is measured with the same probe as the nebulizer
temperature, shown in Figure 5. The measurement is taken before the experiment is
started; the probe is then relocated to the head of the nebulizer.
The relative humidity is measured with a Honeywell HIH-4000 integrated circuit
humidity sensor6 . The small size of the sensor allows it to be easily attached to the
existing particle size distribution measurement hookup, while remaining unobtrusive. It
can register relative humidity values between 0% and 100%, making it appropriate for
any possible climate simulation. While ambient properties are not possible to manipulate
in the field, delivery times, pressure, and vaccine constitution parameters can be adjusted
to minimize the effects of relative humidity and local temperature for a given region.
2.4 Particle Size Distribution
The size of the aerosolized particles is arguably the most important parameter to
ensuring successful vaccination of the patient5. In vivo studies in adults have suggested a
maximum particle size of 5 pim, while studies in children 4 years and younger suggest a
cutoff of 4 pim. There is little in vivo data available for infants; consensus is that the
appropriate maximum particle size is 4 ptm or less 5 .
Particles classified as too large (greater than 5 rim) will be unable to infiltrate
below the vocal chords in an adult to the correct location for vaccine delivery, even
though they carry a substantial amount of vaccine. Conversely, particles that are too
small (less than 1 pm) will have the ability to penetrate and disperse within the lungs, but
will not carry enough drug to effectively vaccinate the patient 5. Trials completed with
the Aerovax experimental setup will use these predetermined particle sizes as a guideline.
Nicholson indicated that measurement of the Aerovax particle size distribution
was to be completed with Malvern Spraytec Laser Diffraction instrument6 . For the
purposes of this experiment, a device was constructed that measures the same qualitative
properties as the Malvern Spraytec instrument, shown in Figure 6.
Figure 6. Device to measure particle size distribution. The laser pointer is aimed
at the photoresistor and the nebulizer is held under the beam. The aerosol
particles interrupt the light, and the amount of light blocked is measured.
A laser pointer is aimed at a photoresistor, which measures a constant light
intensity when there are no particles present. The nebulizer is held under the laser beam
and the vaccine (or for basic experimental purposes, water) is aerosolized, interrupting
the constant beam of light, as shown in Figure 7.
Figure 7. Aerosol being produced during nebulization. It interrupts the constant
beam of light aimed at the photoresistor, and the resistor measures how much of
the beam is blocked by the particles.
Smaller particles block less light than larger particles, showing a relationship
between particle size and the amount of light allowed through to the resistor. This
relationship can eventually be used to determine the actual size of the aerosolized
particles.
The output from the device is a voltage that corresponds to particle size. The
current setup allows for qualitative, but not quantitative, measurement; the particle sizes
can be compared to each other, but their actual sizes still need to be calibrated for
quantitative measures. During experiments, the target particle sizes will be between 3 im
and 5 pim.
3. Results
3.1 Pressure
With an input of 12 V, the compressor output was 250 psi. The transducer
decreased this pressure to a minimum of 3 psi with an input of 0 V. With a 10 V input,
the maximum pressure output by the transducer was 25 psi, not the expected maximum of
27 psi. However, 25 psi was sufficient for the nebulizer to produce a visible aerosol,
shown in Figure 7, that was detectable by the photoresistor. In the next setup, the
transducer will be replaced by a model with which a higher range of pressures can be
output. This will make the range of pressure available to the system more inclusive of all
possible pressure values for aerosolization.
3.2 Ambient Temperature and Relative Humidity
A first order approximation of the relative humidity measured by the sensor can
be determined by the equation
Vut = VSup NY ((0.0062 - SensorRH) + 0.16) (1)
where V0u, is the voltage output by the sensor, Vupply is the 5 V supplied to the sensor, and
Sensor RH is the relative humidity to be solved for8 .
The temperature sensor was successfully attached to the system and will be able
to record temperature measurements in future experiments.
3.3 Particle Size Distribution
Figure 8 shows a trial of the particle size detector measuring the particles in a
water aerosol produced by pressure input with the use of a foot pump. The relationship
depicted is between the resistance of the photodetector, which correlates to light
amplitude, and time. The resistance was measured by the voltage across a resistance-
based voltage divider. The peaks in the graph depict when no aerosol is present and the
detector is picking up the uninterrupted light beam of the laser. The troughs show when a
strong surge of aerosol is interrupting the laser beam. The drift observed in the graph
was a result of the manual setup and was not observed in future iterations with steady
pressure inputs.
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Figure 8. Results from a preliminary trial with a manual setup of the particle size
distribution measurement device. A foot pump was used as a pressure source.
Figures 9a and 9b show the laser beam being interrupted by nebulized water
during a test. The steady plateau at the beginning and end of both figures shows the
constant voltage value reported by the photoresistor when the laser is aimed at it and no
aerosol is present. The decrease shown in both figures occurs when the compressor is
powered on and causes nebulization.
Voltage
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Figure 9a. Voltage reported by the photoresistor over time. The decrease occurs
when aerosol interrupts the laser beam. The pressure input was from the
compressor setup.
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Figure 9b. A different set of results for the same experiment described in Figure
9a.
These initial readings allow for a qualitative comparison between different
particle size distributions. Compared to voltage ouput a in Figure 9a, voltage output b in
Figure 9b is larger. This suggests that less of the laser beam was blocked during the
second trial, because the voltage output measured was closer to the initial value. It can be
inferred that the overall particle size distribution for the trial shown in Figure 9b was the
smaller of the two, and it can be hypothesized for future measurements that the larger the
voltage output recorded, the smaller the particle size distribution of the aerosol.
4. Future of Aerovax
4.1 Optimization of Powdered Measles Vaccine
Using the system constructed, ambient properties, nebulizer geometry, and
vaccine reconstitution can be adjusted to find the ideal parameters for producing an
aerosol particle size of 3 jtm to 5 jim.
To simulate the climates where Aerovax will operate, the ambient temperature
and relative humidity of the experimental area will be altered. The temperature can be
varied with the Amana Dryer Element Restring kit6 , which is a simple heating coil. The
relative humidity will be modified with a Honeywell QuietCare Cool Moisture
Humidifier (HCM650)6.
This initial setup allows for switching to other geometries of jet nebulizers. While
it is recognized that nebulizer shape has an effect on the properties of the aerosol it
produces, there has been little research done that ties different aspects of the nebulizer
geometry to attributes of the aerosol output. Nebulizer elements of interest include the jet
nozzle diameter, the baffle surface area, and the distance between them6 , shown in Figure
10.
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Figure 10. Diagram of a standard jet nebulizer6.
Future iterations of the Aerovax experimental setup will include different forms
of the jet nebulizer that vary the specified properties. An attempt will be made to connect
any changes noted in the aerosol particle size distribution or nebulizer temperature to
features of the nebulizer geometry6.
If the current particle distribution measurement device proves too primitive, it will
be replaced by the Malvern Spraytec Laser Diffraction instrument. The pressure
transducer will also need to be replaced by a model that offers a higher range of pressure
outputs (see Section 3.1), as the current model does not reach the maximum pounds per
square inch needed for thorough aerosolization experimentation.
Reconstitution is the process by which the powder form of the vaccine is prepared
for aerosolization. To guarantee proper sterility, potency, and overall safety, the correct
type and amount of diluent must be used to dissolve each kind of vaccine 2. Buffer
solution and solute concentration are the defining variables of reconstitution. It should be
noted that the solute, or vaccine, concentration tends to increase with time. This is
caused by water evaporation from the solution at a rate faster than that of nebulization .
The amount of buffer solution and solute influences the vaccine's surface tension, pH,
and viscosity. Each of these factors then has an effect on droplet formation during
nebulizations. Surface tension, pH, and viscosity can be varied independently of each
other in future Aerovax experiments dealing directly with the measles vaccine, as laid out
by Nicholson6 .
Ultimately, the Aerovax experimental setup will contain a self-correcting
feedback loop such that the parameters automatically adjust for the best possible
outcome, which will depend on the aerosol fingerprint for the particular vaccine being
tested. The optimization loop will vary pressure in an attempt to attain the most
favorable particle size distribution for lung deposition in different conditions.
4.2 Extension to Other Vaccines
While Aerovax is currently intended for use with the measles vaccination, there is
nothing prohibiting the expansion of its use to study other types of vaccines. Ultimately,
a goal of the project is to have Aerovax operable with as many vaccines as possible.
Measles was the chosen vaccine of focus for the first run of Aerovax because of its
pervasiveness in the developing world. However, there are many other common diseases
that can be prevented with appropriate vaccination. These include, but are not limited to,
pertussis, tetanus, polio, hepatitis (A and B), influenza, meningococcus, diphtheria, and
yellow fever.
Parameters would need to be redefined for each vaccine; for example, certain
ambient temperature and relative humidity values might influence a new vaccine's
particle size distribution differently than they influenced the particle size distribution of
the measles vaccine. The setup design and measurement techniques could remain the
same, although preparation of the vaccine assays would need to be considered
individually based on the unique biochemistry of each virus.
5. Conclusion
Vaccination by injection is not a viable solution for the mass measles
immunization that is necessary in the developing world; an alternative method is needed.
Inhalable vaccination has been verified as safe and equally effective as vaccination by
subcutaneous injection. Aerovax will extend vaccination coverage to those for whom
safe vaccination is not currently a possibility.
The setup presented in this thesis provides a foundation for future
experimentation to determine the best method of delivering the aerosolized vaccine to the
patient. The working model provides an input pressure that can be varied, nebulizer
temperature measurement, and a device to gauge particle size distribution.
This setup is just the beginning of the optimization process. Future experiments
will define the aerosol fingerprint 6 for the measles vaccine and for other selected
vaccines. This research is the first attempt to optimize aerosolized vaccines across
multiple parameters, and will ultimately lead to the development of a vaccination device
appropriate for use in the developing world.
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